Literature DB >> 7536366

Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity.

H B Carter1, J D Pearson, Z Waclawiw, E J Metter, D W Chan, H A Guess, P C Walsh.   

Abstract

OBJECTIVES: To evaluate short-term and long-term variability between prostate-specific antigen (PSA) measurements to determine the most appropriate PSA sampling interval and rate of PSA change (PSA velocity) to distinguish between men with and without prostate cancer.
METHODS: Retrospective study of PSA variability and PSA velocity in three groups of men without a diagnosis of prostate cancer and PSA levels less than 10 ng/mL: 56 men with a histologic diagnosis of benign prostatic hyperplasia (BPH; histologic BPH group) and 527 men with no history of cancer (noncancer group) who were part of the Baltimore Longitudinal Study of Aging and had PSA sampled at 2-year intervals (long-term), and 223 men with a clinical diagnosis of BPH (clinical BPH group) who had PSA sampled at 3-month intervals (short-term). PSA variability (deviation between consecutive measurements) and PSA velocity based on both two consecutive measurements and three consecutive measurements (average velocity) were calculated for each study group.
RESULTS: PSA velocity is the deviation in PSA measurements relative to the elapsed time between the measurements. Because the variability in PSA between measurements was similar for the groups, the major factors that influenced PSA velocity were the sampling interval between PSA measurements, and to a lesser extent, the number of repeat PSA measurements. The 99th percentile for PSA velocity was 0.7 (histologic BPH group) and 0.75 ng/mL per year for the noncancer group when three measurements with a 24-month PSA sampling interval were used. However, the 99th percentile for PSA velocity was 5.8 and 2.4 ng/mL per year when three measurements with 3-month and 6-month PSA sampling intervals were used. Using three measurements, the percentage of subjects with a PSA velocity more than 0.75 ng/mL per year was 1% for the groups with a 24-month PSA sampling interval and 28% and 17% for 3-month and 6-month PSA sampling intervals, respectively. The 99th percentile for PSA velocity and the percentage of subjects with a PSA velocity more than 0.75 ng/mL per year was higher using two measurements compared to three measurements regardless of PSA sampling interval.
CONCLUSIONS: PSA velocity is inversely related to the interval between PSA measurements. A PSA velocity more than 0.75 ng/mL per year is useful in distinguishing between men with and without prostate cancer when: (1) velocity is based on three consecutive measurements; and (2) PSA is sampled long-term (2 years) but not short-term (3 to 6 months).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536366     DOI: 10.1016/S0090-4295(99)80049-1

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  17 in total

1.  The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease.

Authors:  Stacy Loeb; Anna Kettermann; Luigi Ferrucci; Patricia Landis; E Jeffrey Metter; Ballentine H Carter
Journal:  Eur Urol       Date:  2008-08-03       Impact factor: 20.096

Review 2.  Risk-based prostate cancer screening: who and how?

Authors:  Allison S Glass; K Clint Cary; Matthew R Cooperberg
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

3.  Sixteen-year longitudinal changes in serum prostate-specific antigen levels: the olmsted county study.

Authors:  Steven J Jacobsen; Debra J Jacobson; Michaela E McGree; Jennifer L St Sauver; George G Klee; Cynthia J Girman; Michael M Lieber
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

Review 4.  Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics.

Authors:  H Ballentine Carter
Journal:  Asian J Androl       Date:  2012-02-20       Impact factor: 3.285

Review 5.  Tumor markers in prostate cancer I: blood-based markers.

Authors:  Shahrokh F Shariat; Axel Semjonow; Hans Lilja; Caroline Savage; Andrew J Vickers; Anders Bjartell
Journal:  Acta Oncol       Date:  2011-06       Impact factor: 4.089

Review 6.  Risk-based prostate cancer screening.

Authors:  Xiaoye Zhu; Peter C Albertsen; Gerald L Andriole; Monique J Roobol; Fritz H Schröder; Andrew J Vickers
Journal:  Eur Urol       Date:  2011-11-24       Impact factor: 20.096

7.  A quantitative model for the dynamics of serum prostate-specific antigen as a marker for cancerous growth: an explanation for a medical anomaly.

Authors:  K R Swanson; L D True; D W Lin; K R Buhler; R Vessella; J D Murray
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

8.  Retrospective descriptive analysis of the physiological kinetics of prostate-specific antigen in men older than 75 years.

Authors:  Maria Chiara Sighinolfi; Salvatore Micali; Stefano De Stefani; Arrigo Cicero; Filippo Cianci; Marco Giacometti; Giampaolo Bianchi
Journal:  Asian J Androl       Date:  2009-05-18       Impact factor: 3.285

Review 9.  Screening for prostate cancer: an update.

Authors:  Shahrokh F Shariat; Peter T Scardino; Hans Lilja
Journal:  Can J Urol       Date:  2008-12       Impact factor: 1.344

10.  Does extent of prostate-specific antigen fluctuation can predict Gleason score upgrading in low-risk prostate cancer patients?

Authors:  Nurullah Hamidi; Ali Fuat Atmaca; Abdullah Erdem Canda; Murat Keske; Arslan Ardıçoğlu
Journal:  Turk J Urol       Date:  2018-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.